|
|
||||||||||
|
J Am Coll Cardiol, 2005; 45:1295-1301, doi:10.1016/j.jacc.2005.01.045 © 2005 by the American College of Cardiology Foundation |








,*
* Department of Medicine and Center of Excellence on Aging, School of Medicine, "G. dAnnunzio" University, Chieti, Italy
"G. dAnnunzio" University Foundation, Ce.S.I., Chieti, Italy
SS Annunziata Hospital, Chieti, Italy.
Manuscript received October 22, 2004; revised manuscript received December 17, 2004, accepted January 4, 2005.
* Reprint requests and correspondence: Dr. Paola Patrignani, Dipartimento di Medicina e Scienze dellInvecchiamento, Università "G. dAnnunzio," Via dei Vestini 31, 66013 Chieti, Italy. (Email: ppatrignani{at}unich.it).
OBJECTIVES: We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen.
BACKGROUND: The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease.
METHODS: The incubation of washed platelets with naproxen for 5 min before the addition of aspirin reduced the irreversible inhibition of thromboxane (TX)B2 production by aspirin. The pharmacodynamic interaction between the two drugs was then investigated in four healthy volunteers who received aspirin (100 mg daily) for 6 days and then the combination of aspirin and naproxen for further 6 days: aspirin 2 h before naproxen (500 mg, twice-daily dosing). After 14 days of washout, naproxen was given 2 h before aspirin for further 6 days.
RESULTS: The inhibition of serum TXB2 production (index of platelet cyclooxygenase [COX]-1 activity) and platelet aggregation ex vivo and urinary 11-dehydro-TXB2 levels (index of TXB2 biosynthesis in vivo) by aspirin alone (99 ± 0.2%, 95 ± 0.6%, and 81 ± 4%, respectively) was not significantly altered by the co-administration of naproxen, given either 2 h after aspirin or in reverse order. In a second study, the concurrent administration of a single dose of aspirin and naproxen did not affect platelet TXB2 production and aggregation at 1 h after dosing, when aspirin alone causes maximal inhibitory effect. Moreover, the rapid recovery of platelet COX-1 activity and function supports the occurrence of a pharmacodynamic interaction between naproxen and aspirin.
CONCLUSIONS: Naproxen interfered with the inhibitory effect of aspirin on platelet COX-1 activity and function. This pharmacodynamic interaction might undermine the sustained inhibition of platelet COX-1 that is necessary for aspirins cardioprotective effects.
| |||||||||||
Related Article
J. Am. Coll. Cardiol. 2005 45: 1302-1303.
This article has been cited by other articles:
![]() |
N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Schwartz, A. L. Dallob, P. J. Larson, O. F. Laterza, J. Miller, J. Royalty, K. M. Snyder, D. L. Chappell, D. A. Hilliard, M. E. Flynn, et al. Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX-2 Versus COX-1 in Healthy Subjects J. Clin. Pharmacol., June 1, 2008; 48(6): 745 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas Hypertension in rheumatoid arthritis Rheumatology, May 29, 2008; (2008) ken159v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Patrignani, M. L Capone, and S. Tacconelli NSAIDs and cardiovascular disease Heart, April 1, 2008; 94(4): 395 - 397. [Full Text] [PDF] |
||||
![]() |
G. A. FitzGerald Summary Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s51 - s52. [Full Text] [PDF] |
||||
![]() |
C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Gengo, L. Rubin, M. Robson, M. Rainka, M. F. Gengo, D. E. Mager, and V. Bates Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis J. Clin. Pharmacol., January 1, 2008; 48(1): 117 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Snoep, M. M. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, and M. V. Huisman Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events: A Systematic Review and Meta-analysis Arch Intern Med, August 13, 2007; 167(15): 1593 - 1599. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Capone, S. Tacconelli, M. G. Sciulli, P. Anzellotti, L. Di Francesco, G. Merciaro, P. Di Gregorio, and P. Patrignani Human Pharmacology of Naproxen Sodium J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 453 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M E Farkouh, J D Greenberg, R V Jeger, K Ramanathan, F W A Verheugt, J H Chesebro, H Kirshner, J S Hochman, C L Lay, S Ruland, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Ann Rheum Dis, June 1, 2007; 66(6): 764 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. White Cardiovascular Effects of the Cyclooxygenase Inhibitors Hypertension, March 1, 2007; 49(3): 408 - 418. [Full Text] [PDF] |
||||
![]() |
S. Chaiamnuay, J. J. Allison, and J. R. Curtis Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1837 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Bhatt NSAIDS and the risk of myocardial infarction: do they help or harm? Eur. Heart J., July 2, 2006; 27(14): 1635 - 1636. [Full Text] [PDF] |
||||
![]() |
C. Patrono, L. A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med., December 1, 2005; 353(22): 2373 - 2383. [Full Text] [PDF] |
||||
![]() |
M. Hermann, H. Krum, and F. Ruschitzka To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk Circulation, August 16, 2005; 112(7): 941 - 945. [Full Text] [PDF] |
||||
![]() |
S. R. Steinhubl The use of anti-inflammatory analgesics in the patient with cardiovascular disease: What a pain J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1302 - 1303. [Full Text] [PDF] |
||||
![]() |
S. Fries and T. Grosser The Cardiovascular Pharmacology of COX-2 Inhibition Hematology, January 1, 2005; 2005(1): 445 - 451. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |